Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.
about
Bone health and associated metabolic complications in neuromuscular diseasesRole of denosumab in prostate cancer.Osteoclasts: more than 'bone eaters'.The effects of PTH, loading and surgical insult on cancellous bone at the bone-implant interface in the rabbit.Emerging therapies in metastatic bone pain.Soluble guanylate cyclase as a novel treatment target for osteoporosis.μCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy.Teriparatide Therapy as an Adjuvant for Tissue Engineering and Integration of Biomaterials.Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclastsRegulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostinDenosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases.Intermittent PTH administration and mechanical loading are anabolic for periprosthetic cancellous bone.Monocyte chemoattractant protein-1 is a mediator of the anabolic action of parathyroid hormone on bone.Enhanced individual trabecular repair and its mechanical implications in parathyroid hormone and alendronate treated rat tibial bone.Release of bone markers in immediately loaded and nonloaded dental implants: a randomized clinical trial.Mechanisms of osteoclast-dependent bone formation.Parathyroid Hormone (1-34) Might Not Improve Early Bone Healing after Sinus Augmentation in Healthy Rabbits.Bone biology and anabolic therapies for bone: current status and future prospects.A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment.Individual and combining effects of anti-RANKL monoclonal antibody and teriparatide in ovariectomized mice.Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities.Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.Novel techniques in the development of osteoporosis drug therapy: the osteoclast ruffled-border vacuolar H(+)-ATPase as an emerging target.Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton.Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells.The skeletal impact of the chemotherapeutic agent etoposide.One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.Three-dimensional image registration improves the long-term precision of in vivo micro-computed tomographic measurements in anabolic and catabolic mouse models.The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study.An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6.Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.The effect of etidronate on the periodontium of ovariectomized rats.A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice.Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.Overexpression of Gα11 in Osteoblast Lineage Cells Suppresses the Osteoanabolic Response to Intermittent PTH and Exercise.RANKL blockade prevents and treats aggressive osteosarcomas.Suppression of p38α MAPK Signaling in Osteoblast Lineage Cells Impairs Bone Anabolic Action of Parathyroid Hormone.Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosisPharmacological inhibition of Dock5 prevents osteolysis by affecting osteoclast podosome organization while preserving bone formation
P2860
Q27025688-AF6B68D6-D002-4B8E-B831-6F84975DDA19Q30455154-B1EE5CA2-BADB-478F-A8D6-1BB247D96D2FQ33993757-2152F0DE-B0D6-4B28-B2A9-60339C267893Q34079954-D1372FB8-1DCA-4E36-9A7F-057337AC717AQ34182919-976D7ADD-6A58-4308-9E61-CBC7CA352816Q34551704-4DF54543-AD4A-4DA5-96E9-5995424F10C7Q35108947-4D85C215-5C0A-4348-B011-D0344067449EQ35165694-E6699E33-69F2-4BCA-8D54-C7B5D4390C8EQ35378487-E1E7EDCB-0C7A-42CD-85ED-54CDBEC91CA0Q36236285-B67BE1B5-DDEE-4A90-ACCF-D6434F1DD8C2Q36524611-D5766ECC-26BE-48A6-AAD4-167714F80CB7Q36647074-117218A0-8CFE-4E72-ACE9-61253A76A382Q37110385-71C8B756-16E7-4044-B0DE-B6D18FA7E0A8Q37370284-796FCFC3-453D-4152-A378-C00FEEF9A55FQ37385579-B53494B3-96FD-47BB-8FC6-7643CA18F758Q37414413-695DCB6E-1367-49F6-BE99-494C7C3BD6B3Q37661167-6FE28A64-E343-4CDA-AD41-2B7261814750Q37673469-57420576-4619-43DC-B6D5-8D32903E4D71Q37679606-8B0ACE6F-9285-42DF-8099-AF241FB88382Q37720404-2E3BAADD-6C18-4593-8D3B-33C00B176AB6Q38047183-04755FCE-BE26-4B77-8E33-FBDA509CE747Q38183262-AE133AC7-8C50-4B41-B7A5-2164D6B3B72CQ38205860-8E5D47D0-C60C-4106-898F-15B904C4DA2FQ38230277-E01A3AD5-E044-4FEC-90A9-29F1C2AD9A43Q38257484-21F55461-1263-4A61-8E7F-90181C4A3B59Q38661460-4C767907-C8E8-43C2-A56A-135A3BA989AAQ38827517-82195DA9-2B3E-47B0-A5C0-2CDA111D1D51Q39283452-B6A06994-010F-497C-AD2E-0D26E18667EAQ39324421-7631FDC6-FA1C-42BB-A509-8B926DF80A4DQ41989650-17D82683-0948-49F9-BF28-D08339B7AE36Q44216694-6B144C23-4DF0-458D-A01B-2D27C5AD6798Q46583319-0E161F84-9ACD-43FC-AFD9-92B8EC78E847Q46851946-0614A0CA-A3C8-490E-B80F-35EB4244CE1BQ46907891-0F763267-0DE7-493E-A362-AEFFAACE8832Q48986728-566FB239-8247-42C5-BFAE-F3FB4F0EF669Q51703751-B55C64E6-3EE9-467D-91FC-0F13DE2D8E35Q54228752-BD968AD2-CCF5-47B2-8148-9264A4CD2D32Q54229745-A1078766-266C-44DC-B3DB-D2617F1ADA0FQ57217564-B73F9167-CD15-42F2-BC0A-2A9FA5BA1CDAQ57976931-A7BD8A9E-8CD6-464B-8F6B-8231956237B0
P2860
Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Are osteoclasts needed for the ...... ce expressing humanized RANKL.
@ast
Are osteoclasts needed for the ...... ce expressing humanized RANKL.
@en
Are osteoclasts needed for the ...... ce expressing humanized RANKL.
@nl
type
label
Are osteoclasts needed for the ...... ce expressing humanized RANKL.
@ast
Are osteoclasts needed for the ...... ce expressing humanized RANKL.
@en
Are osteoclasts needed for the ...... ce expressing humanized RANKL.
@nl
prefLabel
Are osteoclasts needed for the ...... ce expressing humanized RANKL.
@ast
Are osteoclasts needed for the ...... ce expressing humanized RANKL.
@en
Are osteoclasts needed for the ...... ce expressing humanized RANKL.
@nl
P2093
P2860
P356
P1476
Are osteoclasts needed for the ...... ice expressing humanized RANKL
@en
P2093
Dominique D Pierroz
Marina Stolina
Michael S Ominsky
Paul A Baldock
Paul J Kostenuik
Serge L Ferrari
P2860
P304
28164-28173
P356
10.1074/JBC.M110.101964
P407
P577
2010-06-17T00:00:00Z